Advil NDA approval
This article was originally published in The Tan Sheet
Executive Summary
Wyeth Consumer Healthcare receives agency clearance for Advil Cold & Sinus Liquigels May 30. Approved under NDA 21-374, liquigels contain 200 mg ibuprofen, 30 mg pseudoephedrine hydrochloride for "temporary relief" of cold, sinusitis or flu symptoms. Wyeth could be looking to spark new life into its cold and allergy brands, which collectively saw food, drug, mass sales drop 14% to $86 mil. for the 52 weeks ended April 21, according to data from Information Resources, Inc. (Chicago). Advil Cold & Sinus products currently rank ninth in the category, with 52-week sales totaling $40.2 mil. (down 5.2%); the line debuted in 1989. Approval is second this year for Wyeth's Advil franchise; firm will extend its pediatric line with Children's Advil Cold by year end (1"The Tan Sheet" April 29, 2002, p. 5)...
You may also be interested in...
Wyeth Children’s Advil Cold Combination Suspension Extends Pediatric Line
Wyeth Consumer Healthcare's Advil franchise will expand into the pediatric cold category with Children's Advil Cold ibuprofen/pseudoephedrine oral suspension, which is slated to launch later this year
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.